Voigt H, Reuter W, Hofmann B, Dobberkau A
Klinik für Innere Medizin, Bereichs Medizin der Karl-Marx-Universität Leipzig.
Z Gesamte Inn Med. 1990 May 15;45(10):283-7.
In a double blind study altogether 41 patients with obliterating arteriosclerosis at stage II after Fontaine have been treated for 26 weeks either with 3 X 100 mg Trapidil (Rocornal) daily or placebo. In the second half of the study under Trapidil in contrast to placebo a clinically relevant additional increase of the distance of the intermitent claudication was the result. On the other hand, the plethysmographically measured reserve of the arterial blood supply did not show any changes in the two groups. A specific influence of Trapidil on the lipoprotein metabolism is apparently not present, since there appeared favourable influence on the hyperlipoproteinaemia diagnosed in 37 out of 41 patients both under placebo and under Trapidil.
在一项双盲研究中，共41例处于Fontaine II期的闭塞性动脉硬化患者，接受了为期26周的治疗，一组每日服用3次，每次100毫克曲匹地尔（Rocornal），另一组服用安慰剂。在研究的后半段，与安慰剂组相比，服用曲匹地尔的患者间歇性跛行距离出现了临床上有意义的额外增加。另一方面，两组经体积描记法测量的动脉血供储备均未显示出任何变化。曲匹地尔对脂蛋白代谢显然没有特定影响，因为在安慰剂组和曲匹地尔组中，41例患者中有37例被诊断为高脂蛋白血症，均出现了有利影响。
